Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease

An Open-Label, Multi-Center, Single Arm Study to Evaluate the Effects of Azilect® on Sleep Disturbances in Parkinson's Disease Subjects

The main objective of this study is to evaluate the effect of Azilect® on sleep disturbances in Parkinson's Disease patients, after 2 months of treatment.

Inclusion Criteria:

• idiopathic Parkinson's disease.
• eligible to Azilect® treatment as per Canadian product monograph

Exclusion Criteria:

• exclusion (e.g. drug-drug interactions, contraindications, warnings and precautions) based on the Canadian product monograph.
• investigational drug within 30 days prior to study
• use of Azilect® or selegiline within 60 days prior to study
• significant medical condition